PASylated factor VIII - XL-protein GmbH

Drug Profile

PASylated factor VIII - XL-protein GmbH

Alternative Names: GNR-021; PAS-clotting factor; xl-180

Latest Information Update: 09 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator XL-protein GmbH
  • Developer International Biotechnology Center Generium; XL-protein GmbH
  • Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements; Factor VIII stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Haemophilia A

Most Recent Events

  • 09 Aug 2016 Early research is ongoing in Germany
  • 09 Aug 2016 Preclinical trials in Haemophilia A in Russia and Commonwealth of Independent States (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top